Fifty years in the vineyard of transplantation: Looking back

Transplantation Proceedings

Volumn 43, Issue 8, 2011, Pages 2853-2859

  Kahan, B D ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 2 [2 [4 (3 BENZYLOXYPHENYLTHIO) 2 CHLOROPHENYL]ETHYL] 1,3 PROPANEDIOL; BASILIXIMAB; BREQUINAR; CYCLOSPORIN A; DEFIBROTIDE; DEXAMETHASONE; ENISOPROST; FINGOLIMOD; HISTOCOMPATIBILITY ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MERCAPTOPURINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; NC 1153; PNU 15684; RAPAMYCIN; TACROLIMUS; UNCLASSIFIED DRUG; UNIPROST;

AMINO ACID SUBSTITUTION; CONFERENCE PAPER; DRUG POTENTIATION; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LYMPH NODE IRRADIATION; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; TRANSPLANTATION;

ANIMALS; CLINICAL TRIALS AS TOPIC; HISTOCOMPATIBILITY ANTIGENS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSIVE AGENTS; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTS;

EID: 80054746183     PISSN: 00411345     EISSN: 18732623     Source Type: Journal    
DOI: 10.1016/j.transproceed.2011.08.058     Document Type: Conference Paper

References (87)

1. P.B. Medawar The use of antigenic tissue extracts to weaken the immunologic reaction against skin homografts in mice Transplantation 1 1963 21
2. B.D. Kahan, and R.A. Reisfeld Transplantation antigens Science 164 1969 514
3. B.D. Kahan Isolation of a soluble transplantation antigen Proc Natl Acad Sci (Wash) 53 1965 153
4. B.D. Kahan Cutaneous hypersensitivity reactions of guinea pigs to proteinaceous transplantation antigen J Immunol 99 1967 1121
5. B.D. Kahan, and R.A. Reisfeld Electrophoretic purification of a water-soluble guinea pig transplantation antigen Proc Natl Acad Sci (Wash) 58 1967 1430
6. E.S. Curtoni, P. Matting, and R.M. Tosi Histocompatibility testing 1967 Munksgaard Copenhagen
7. B.D. Kahan, R.A. Reisfeld, and M.A. Pellegrino Water-soluble human transplantation antigen Proc Natl Acad Sci (Wash) 61 1968 897
8. B.D. Kahan, and R.A. Reisfeld Differences in the amino acid compositions of allogeneic guinea pig transplantation antigens J Immunol 101 1968 237
9. R.A. Reisfeld, and B.D. Kahan Markers of biological individuality Sci Am 226 1972 28
10. S.G. Nathenson, and D.A. Davies Solubilization and partial purification of mouse histocompatibility antigens from a membranous lipoprotein fraction Proc Natl Acad Sci (Wash) 56 1966 476
11. R.A. Reisfeld, M.A. Pellegrino, and B.D. Kahan Salt extraction of soluble HL-A antigens Science 172 1971 1134
12. S.J. LeGrue, B.D. Kahan, and N.R. Pellis Extraction of a murine tumor-specific transplantation antigen with I-butanol I. Partial purification by isoelectric focusing J Natl Cancer Inst 65 1980 191
13. S.J. LeGrue, C.M. Macek, and B.D. Kahan Noncytolytic extraction of murine tumor-specific transplantation antigens with the nonionic detergent octyl-beta-D-glucopyranoside J Natl Cancer Inst 69 1982 131
14. B.D. Kahan, K.K. Mittal, and R.A. Reisfeld The antigenic stimulus in human transplantation Surgery 74 1973 153
15. R.E. Billingham, L. Brent, and P.B. Medawar Quantitative studies on tissue transplantation immunity III. Actively acquired tolerance Phil Trans R Soc Lond B 239 1956 357
16. M. Feldman Induction of immunity and tolerance in vitro by hapten protein conjugates I. The relationship between the degree of hapten conjugation and the immunogenicity of dinitrophenylated polymerized flagellin J Exp Med 135 1972 735
17. T. Hamashima, S.M. Stepkowski, and S. Smith Induction of transplantation tolerance by a single intrathymic injection of 3M KCl-extracted (e-HAg) donor histocompatibility antigens combined with two doses of anti-rat alpha/beta-T cell receptor monoclonal antibodies Transplantation [Brief Communication] 58 1994 105
18. T. Tsuda, and B.D. Kahan A potential synergistic effect of donor antigenic extracts and cyclosporine on the prolongation of rat renal allografts Transplantation 35 1983 483
19. T. Yasumura, and B.D. Kahan Prolongation of rat kidney allografts by pretransplant administration of donor antigen extract or whole blood transfusion combined with a short course of cyclosporine Transplantation 36 1983 603
20. S. Goto, S.M. Stepkowski, and B.D. Kahan Benefit of multiple over single doses of 3M KCl-extracted histocompatibility antigen in potentiating cyclosporine-induced prolongation of rat cardiac allograft survival Transplantation 53 1992 705
21. T. Yasumura, and B.D. Kahan Prolongation of allograft survival by repeated cycles of donor antigen and cyclosporine in rat kidney transplantation Transplantation 38 1984 418
22. T. Ito, S.M. Stepkowski, and B.D. Kahan Soluble antigen and cyclosporine-induced specific unresponsiveness in rats Frequency of alloantigen-specific T cytotoxic cells in normal, sensitized, and unresponsive rats Transplantation 49 1990 422
23. N. Yoshimura, and B.D. Kahan Nature of the suppressor cells mediating prolonged graft survival after administration of extracted histocompatibility antigen and cyclosporine Transplantation 39 1985 162
24. N. Yoshimura, and B.D. Kahan The immunosuppressive action of suppressor cells from antigen-cyclosporine-treated hosts on renal allograft survival Transplantation 40 1985 384
25. N.R. Pellis, H. Yamagishi, and C.M. Macek Specificity and biological activity of extracted murine tumor-specific transplantation antigens Int J Cancer 26 1980 443
26. R. Ghobrial, T. Hamashima, and S.M. Stepkowski Induction of transplantation tolerance by chimeric donor/recipient class I RT1.Aa molecules Transplantation 62 1996 1002
27. M. Wang, S.M. Stepkowski, and J. Yu Localization of cryptic tolerogenic epitopes in the α1-helical region of the RT1.Au alloantigen Transplantation [Rapid Communication] 63 1997 1373
28. S.M. Stepkowski, R.A. Kirken, and B.W. Trawick Allochimeric class IMHC protein-induced tolerance by partial TCR engagement requires activation of both CTL4- and common gamma-chain-dependent cytokine signals Transplantation 73 2002 1227
29. N.V. Semiletova, X.D. Shen, and S.J. Slomowitz Allochimeric therapy induces unique regulatory T cells that mitigate chronic rejection Transplant Proc 37 2005 35
30. W. Lisik, Y. Gong, and N. Tejpal Intragraft gene expression profile associated with the induction of tolerance by allochimeric MHC I in the rat heart transplantation model Genesis 48 2010 8
31. B.D. Kahan Editorial: Cosmas and Damian in the 20th century? N Engl J Med 305 1981 280
32. B.D. Kahan, C.T. Van Buren, and S.M. Flechner Cyclosporine immunosuppression mitigates immunologic risk factors in renal allotransplantation Transplant Proc 15 suppl 1 1983 2469
33. B.D. Kahan, C.T. Van Buren, and S.M. Flechner Clinical and experimental studies with cyclosporine in renal transplantation Surgery 97 1985 125
34. T.E. Starzl, T.R. Hakala, and J.T. Rosenthal The Colorado-Pittsburgh Cadaveric Renal Transplantation Study with Cyclosporine Transplant Proc 15 4 suppl 1 1983 2459
35. J.S. Najarian, M. Strand, and D.S. Fryd Comparison of cyclosporine versus azathioprine-antilymphocyte globulin in renal transplantation Transplant Proc 15 4 suppl 1 1983 2463
36. B.D. Kahan, M. Ried, and J. Newburger Pharmacokinetics of cyclosporine in human renal transplantation Transplant Proc 15 1983 446
37. B.D. Kahan, C.A. Wideman, and M. Ried The value of serial serum trough cyclosporine levels in human renal transplantation Transplant Proc 16 1984 1195
38. B.D. Kahan Individualization of cyclosporine therapy using pharmacokinetic and pharmacodynamic parameters Transplantation 40 1985 457
39. B.D. Kahan, and J. Grevel Overview: optimization of cyclosporine therapy in renal transplantation by a pharmacokinetic strategy Transplantation 46 1988 631
40. A. Lindholm, and B.D. Kahan Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation Clin Pharmacol Ther 54 1993 205
41. B.D. Kahan, M. Welsh, and D.L. Urbauer Low intraindividual variability of cyclosporine A exposure reduces chronic rejection incidence and health care costs J Am Soc Nephrol 11 2000 1122
42. B.D. Kahan, J. Dunn, and C. Fitts The Neoral Formulation: Improved correlation between cyclosporine trough level and exposure in stable renal transplant recipients Transplant Proc 26 1994 2940
43. A.J. Amante, and B.D. Kahan Abbreviated area-under-the-curve strategy for monitoring cyclosporine microemulsion therapy in immediate posttransplant period Clin Chem 42 1996 1294
44. K. Mahalati, J. Lawen, and B. Kiberd Is 3-hour cyclosporine blood level superior to trough level in early post-renal transplantation period? J Urol 163 2000 37
45. G. Levy, G.L. Grazi, and F. Sanjuan 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus Liver Transpl 12 2006 1464
46. R.H. Didlake, K.K. Dreyfus, and R.H. Kerman Patient noncompliance: a major cause of late graft failure in cyclosporine-treated renal transplants Transplant Proc 20 suppl 3 1988 63
47. G. Feutren, and M.J. Mihatsch Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases N Engl J Med 326 1992 1654
48. B.D. Kahan, P.R. Rajagopalan, and M. Hall United States Simulect® Renal Study Group: reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody Transplantation 67 1999 276
49. B.D. Kahan Mycophenolate mofetil Chapter 18 P.J. Morris, S. Knechtle, Kidney transplantation 6th ed. 2008 Saunders Philadelphia 277
50. A. Vathsala, T.-C. Chou, and B.D. Kahan Analysis of the interactions of immunosuppressive drugs with cyclosporine in inhibiting DNA proliferation Transplantation 49 1990 463
51. A. Vathsala, S. Goto, and N. Yoshimura The immunosuppressive antagonism of low doses of FK506 and cyclosporine Transplantation 52 1991 121
52. B.D. Kahan, S. Gibbons, and N. Tejpal Synergistic interactions of cyclosporine and rapamycin to inhibit immune performances of normal human peripheral blood lymphocytes in vitro Transplantation 51 1991 232
53. M.G. Murgia, S. Jordan, and B.D. Kahan The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients Kidney Int 49 1996 209
54. B.D. Kahan, J. Podbielski, and K.L. Napoli Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation Transplantation 66 1998 1040
55. B.D. Kahan, B.A. Julian, M.D. Pescovitz Rapamune Study Group Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in Caucasian recipients of mismatched primary renal allografts: a phase II trial Transplantation 68 1999 1526
56. B.D. Kahan Rapamune U.S. Study Group Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study Lancet 356 2000 194
57. A.S. MacDonald RAPAMUNE Global Study Group A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts Transplantation 71 2001 271
58. B.D. Kahan Two-year results of multicenter phase III trials on the effect of addition of sirolimus to cyclosporine-based immunosuppressive regimens in renal transplantation Transplant Proc 35 2003 37S
59. K.L. Napoli, and B.D. Kahan Sample clean-up and high performance liquid chromatography techniques for measurement of whole blood rapamycin concentrations J Chromatogr 654 1994 111
60. H. Podder, S.M. Stepkowski, and K. Napoli Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations J Am Soc Nephrol 12 2001 1059
61. S.M. Flechner, M. Glyda, and S. Cockfield The ORION Study: Comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients Am J Transplant 11 2001 1633
62. B.D. Kahan, R.L. Wong, and C. Carter A phase I study of a 4-week course of SDZ-RAD (RAD) in quiescent cyclosporine-prednisone-treated renal transplant recipients Transplantation 68 1999 1100
63. J.M. Kovarik, B. Kaplan, and H. Tedesco Silva Pharmacokinetics of an everolimus-cyclosporine regimen over the first 6 months after kidney transplantation Am J Transplant 3 2003 606
64. B.D. Kahan, C. Benavides, and L. Schoenberg Addition of induction therapy offsets the hazard of marked calcineurin minimization among renal transplant recipients treated with sirolimus Clin Nephrol 73 2010 344
65. J. Pliszczynski, and B.D. Kahan Better actual 10-year renal transplant outcomes of 80% reduced cyclosporine exposure with Sirolimus base therapy compared with full cyclosporine exposure without or with concomittant sirolimus treatment Transplant Proc 43 2011 (in press)
66. R. Pollak, R. Knight, and M.F. Mozes A trial of the prostaglandin E1 analog, Enisoprost, to reverse chronic cyclosporine-associated renal dysfunction Am J Kidney Dis 20 1992 336
67. L.S. Florence, T. Ito, and K. Ang The synergistic effect of total lymphoid irradiation with extracted donor alloantigen to induce transplantation unresponsiveness Transplantation 47 1989 156
68. D.V. Cramer, F.A. Chapman, and B.D. Jaffee The effect of a new immunosuppressive drug, brequinar sodium, on heart, liver, and kidney allograft rejection in the rat Transplantation 53 1992 303
69. B.D. Kahan, N. Tejpal, and S. Gibbons-Stubbers The synergistic interactions in vitro and in vivo of brequinar sodium with cyclosporine or rapamycin alone and in triple combination Transplantation 55 1993 894
70. A.S. Joshi, S.Y.P. King, and B.A. Zajac Phase I safety and pharmacokinetic studies of brequinar sodium after single ascending oral doses in stable renal, hepatic and cardiac allograft recipients J Clin Pharmacol 37 1997 1121
71. R.J. Knight, R. Kurrle, and S.M. Stepkowski Synergistic immunosuppressive actions of cyclosporine with a mouse anti-rat α/β-T cell receptor monoclonal antibody Transplantation 57 1994 1544
72. R.J. Knight, R. Kurrle, and J. McClain Clinical evaluation of induction immunosuppression with a murine IgG2b monoclonal antibody (BMA 031) directed toward the human α/β-T cell receptor Transplantation 57 1994 1581
73. L. Chatenoud, and J.F. Bach T-cell receptor-based immunointervention in autoimmune diseases Therapeutic use of monoclonal antibodies Immunol Ser 59 1993 101
74. K. Wonigeit, B. Nashan, and R. Schwinzer Use of a monoclonal antibody against the T cell receptor for prophylactic immunosuppressive treatment after liver transplantation Transplant Proc 21 1989 2258
75. W. Chen, C.F. Bennett, and M.-E. Wang Perfusion of kidneys with unformulated "naked" intercellular adhesion molecule-1 antisense oligodeoxynucleotides prevents ischemic/reperfusion injury Transplantation 68 1999 880
76. B.D. Kahan, S.M. Stepkowski, and M. Kilic Phase I/II safety-efficacy trial of intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302) in the prevention of acute allograft rejection Transplantation 78 2004 858
77. B.D. Kahan, J.L. Karlix, and R.M. Ferguson Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study Transplantation 76 2003 1079
78. H. Tedesco-Silva, G. Mourad, and B.D. Kahan FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation Transplantation 79 2005 1553
79. Z.H. Tedesco-Silva, M.I. Lorber, C.E. Foster FTY720 2202 clinical study group FTY720 and everolimus in de novo renal transplant patients at risk for delayed graft function: results of an exploratory 1-year, multicenter study Clin Transplant 23 2009 589
80. L.J. Dumble, S. Gibbons, and M. Tejpal 15 AU81, A prostacyclin analog, potentiates immunosuppression and mitigates renal injury due to cyclosporine Transplantation 55 1993 1124
81. M. Ferraresso, P. Rigotti, and S.M. Stepkowski Immunosuppressive effects of defibrotide Transplantation 56 1993 928
82. B.D. Kahan, T. Chou, and N. Tejpal Synergistic effects of cyclosporin analogs - A, D, G, IMM-125 - with rapamycin and/or brequinar Transplant Proc 26 1994 3021
83. R.A. Kirken, R. Erwin-Cohen, and F. Behbod Tyrphostin AG490 selectively inhibits activation of the JAK3/STAT5/MAPK pathway and rejection of rat heart allografts Transplant Proc 33 2001 95
84. S.M. Stepkowski, R.A. Erwin-Cohen, and F. Behbod Selective inhibitor of Janus tyrosine kinase 3, PNU156804, prolongs allograft survival and acts synergistically with cyclosporine but additively with rapamycin Blood 99 2002 680
85. S.M. Stepkowski, J. Kao, and M.E. Wang The Mannich base NC1153 promotes long-term allograft survival and spares the recipient from multiple toxicities J Immunol 175 2005 4236
86. W. Chen, C.F. Bennett, and T.P. Condon Methoxyethyl modification of phosphorothioate ICAM-1 antisense oligonucleotides improves prevention of ischemic/reperfusion injury Transplant Proc 33 2001 854 (Pubitemid 32237656)
87. R. Langer, M.E. Wang, and S.M. Stepkowski Selectin inhibitor bimosiamose prolongs survival of kidney allografts by reduction in intragraft production of cytokines and chemokines J Am Soc Nephrol 15 2004 2893